Literature DB >> 3554490

Beta-adrenoceptor blockade in the treatment of postoperative adynamic ileus.

B Hallerbäck, E Carlsen, K Carlsson, C Enkvist, H Glise, J Haffner, R Innes, K Kirnö.   

Abstract

Abdominal trauma, such as surgery and peritonitis, leads to inhibition of intestinal motility, partly mediated by alpha- and beta-adrenoceptors. To investigate the effect of nonselective beta-blockade on adynamic ileus, propranolol was compared with placebo in the postoperative course after elective colonic surgery in a double-blind randomized study. Ten patients received 4 mg propranolol intravenously twice daily, and ten received 10 mg intravenously twice daily. Nineteen patients received placebo. The time to first passage of stool was 110 +/- 9 h in the placebo group and 82 +/- 11 h in the 4-mg propranolol group. In the 10-mg propranolol group, the time was 79 +/- 8 h. The difference between the placebo-treated group and the propranolol-treated groups was significant (p less than 0.01). The effect of propranolol was most marked in older patients and after surgery on the distal colon. In patients older than 60 years the time to first stool in the placebo group was 127 +/- 13 h (n = 8), compared with 73 +/- 8 h (n = 11) in the propranolol group (p less than 0.01). In patients who had undergone surgery on the distal colon the time to first stool was 125 +/- 13 h (n = 8) in the placebo group and 76 +/- 8 h (n = 11) for propranolol (p less than 0.01). Adverse effects on the respiratory or cardiovascular system were not seen during medication. It is concluded that propranolol shortens the period of adynamic ileus after colonic surgery.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3554490     DOI: 10.3109/00365528708991872

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

Review 1.  Postoperative ileus.

Authors:  H Kehlet
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

Review 2.  Postoperative ileus: progress towards effective management.

Authors:  Kathrine Holte; Henrik Kehlet
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Stimulation of beta-adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans.

Authors:  M Thollander; T H Svensson; P M Hellström
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 4.  Postoperative ileus: impact of pharmacological treatment, laparoscopic surgery and enhanced recovery pathways.

Authors:  Knut Magne Augestad; Conor P Delaney
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

5.  Cisapride reduces postoperative gastrocaecal transit time after cardiac surgery in children.

Authors:  L Bindl; S Buderus; M Ramirez; P Kirchhoff; M J Lentze
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

6.  Effects of epidural buprenorphine on bowel movement following gynecological surgery.

Authors:  Yoshitaka Toyoda; Hiroshi Morisaki; Tomoko Yorozu; Toshiyuki Shigematsu
Journal:  J Anesth       Date:  1995-06       Impact factor: 2.078

Review 7.  Rational pharmacotherapy of gastrointestinal motility disorders.

Authors:  P Demol; H J Ruoff; T R Weihrauch
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

8.  The evolution of postoperative ileus after laparoscopic cholecystectomy. A comparative study with conventional cholecystectomy and sympathetic blockade treatment.

Authors:  M García-Caballero; C Vara-Thorbeck
Journal:  Surg Endosc       Date:  1993 Sep-Oct       Impact factor: 4.584

9.  Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus.

Authors:  Goldina Ikezuagu Erowele
Journal:  P T       Date:  2008-10

10.  Intestinal afferent nerve sensitivity is increased during the initial development of postoperative ileus in mice.

Authors:  M H Mueller; M Karpitschka; B Xue; M S Kasparek; A Sibaev; J Glatzle; M E Kreis
Journal:  J Gastrointest Surg       Date:  2009-01-07       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.